Precision Trading with Atricure Inc. (ATRC) Risk Zones
This article provides an in-depth analysis of Atricure Inc. (NASDAQ: ATRC) based on AI-generated signals. It highlights "divergent sentiment readings" and "elevated downside risk," offering three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry, target, and stop-loss zones. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term horizons, advising on support and resistance levels.
AtriCure (NASDAQ: ATRC) 2026 proxy adds 2.25M shares to equity plans
AtriCure Inc. (NASDAQ: ATRC) will hold its 2026 annual meeting virtually on May 18, 2026, where stockholders will vote on several proposals, including expanding its equity compensation plans. The company seeks to add 1.5 million shares to its 2023 Stock Incentive Plan and 750,000 shares to its 2018 Employee Stock Purchase Plan, totaling 2.25 million additional shares. Other agenda items include the election of nine directors, ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory "say-on-pay" vote for named executive officer compensation.
A Look At AtriCure (ATRC) Valuation After Q4 Growth And Recent Analyst Downgrades
AtriCure (ATRC) experienced a mixed reaction to its Q4 2025 earnings, with 15% revenue growth prompting investor attention despite recent share price declines and analyst downgrades. While Simply Wall St's narrative model suggests the stock is 44.9% undervalued with a fair value of $52.78, its DCF model indicates the current share price of $29.07 is overvalued compared to an estimated future cash flow value of $1.65. This discrepancy highlights differing valuation perspectives and the importance of considering both potential market expansion from clinical trials and risks like competition and development costs.
Should AtriCure’s Q4 Revenue Beat and Cautious Analyst Tone Reshape the ATRC Investment Narrative?
AtriCure (ATRC) recently reported strong Q4 2025 results with a 15% revenue increase and a return to profitability, indicating continued demand for its cardiac and pain management devices. Despite this performance, analyst sentiment remains cautious due to rising competition from pulsed field ablation catheters and execution risks associated with its 2026 guidance. The article explores how this contrast between solid operational results and conservative analyst views is shaping the investment narrative around AtriCure’s future prospects.
AtriCure (NASDAQ:ATRC) Raised to Strong-Buy at Wall Street Zen
AtriCure (NASDAQ:ATRC) was upgraded to a "strong-buy" rating by Wall Street Zen. The company recently reported a quarterly earnings beat with $0.06 EPS against an estimated -$0.04 and revenue of $140.5M, a 13.1% year-over-year increase. Despite mixed analyst coverage and some downgrades, the stock has a consensus target price of $48.43, and institutional ownership remains very high at 99.11%.
ATRC Should I Buy
Intellectia AI recommends holding AtriCure Inc (ATRC) rather than buying, especially for beginner, long-term investors, due to declining net income and EPS despite revenue growth, coupled with significant competition. Technical indicators show mixed signals, and while some analysts maintain "Buy" ratings, others have downgraded the stock due to competitive risks.
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts
AtriCure, Inc. (NASDAQ:ATRC) has received an average rating of "Moderate Buy" from eleven research firms, with a consensus one-year price target of $48.43. While the company exceeded Q4 EPS estimates and saw revenue growth, it remains unprofitable. Recent insider selling and significant institutional ownership were also noted.
AtriCure (NASDAQ:ATRC) Stock Rating Upgraded by Freedom Capital
Freedom Capital has upgraded AtriCure (NASDAQ:ATRC) to a "strong-buy" rating, though the street consensus remains a "Moderate Buy" with an average target price of $48.43. Despite several recent price target cuts from other brokerages, AtriCure beat EPS expectations in its last quarterly report and saw revenue rise by 13.1%. Institutional ownership is high at approximately 99.11%, while insider Vinayak Doraiswamy recently sold 5,000 shares.
ATRC Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to ATRC stock, including DAFNA Capital Management reducing its stake in a Biotechnology ETF, an AtriCure Chief Scientific Officer selling shares, and UBS lowering its price target for ATRICURE INC. It also highlights AtriCure's strong Q4 2025 earnings report with 15% revenue growth, which exceeded expectations, despite a prior JPMorgan downgrade.
AtriCure, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
AtriCure, Inc. (a small-cap pharmaceutical and biotechnology company) has seen a decline in its stock price and performance, with technical indicators suggesting bearish sentiment. The stock is currently priced at $28.88, significantly down from its previous close, and has lagged behind the S&P 500 over the past year and year-to-date. This trend indicates ongoing challenges for AtriCure in the current market environment.
AtriCure Inc (ATRC) Stock Price Quote Today & Current Price Chart | Capital.com Australia
This page provides current stock price quotes and chart information for AtriCure Inc (ATRC) on Capital.com Australia, a platform for CFD trading. It details trading conditions such as spreads, overnight funding adjustments, margin requirements, and key statistics including previous close, open, and 1-year change. The article also features recent news relevant to the broader market and user reviews of the Capital.com platform.
AtriCure Shares Plunge to New 1-Year Low
Shares of AtriCure, Inc. (NASDAQ:ATRC) have fallen to a new 52-week low of $28.18 following a series of analyst downgrades and price target cuts. Major financial institutions like Zacks Research and Needham & Company have reduced their ratings and price targets due to increased competition and concerns about the company's growth prospects in the cardiac device market. Investors are now awaiting AtriCure's upcoming earnings report for insights into the company’s future strategy.
AtriCure stock hits 52-week low at $28.25 amid market fluctuations
AtriCure Inc. (ATRC) stock hit a new 52-week low of $28.25, reflecting broader market challenges and investor sentiment despite analysts maintaining a positive outlook. The company's recent Q4 revenue surpassed expectations, and adjusted EPS significantly beat estimates. However, analyst reactions have been mixed, with some lowering price targets due to valuation and competitive concerns.
AtriCure Inc (ATRC) Stock Price Quote Today & Current Price Chart
This article provides current stock price information and trading conditions for AtriCure Inc (ATRC) as a CFD instrument on Capital.com. It details key statistics such as previous close, open, 1-year change, and day's range, along with various trading charges like spread and overnight funding adjustments. The page also features recent articles related to other company stocks and customer reviews for Capital.com.
Technical Reactions to ATRC Trends in Macro Strategies
This article provides a technical analysis of Atricure Inc. (NASDAQ: ATRC) trends, outlining near-term strong sentiment, mid-term neutrality, and a long-term positive bias. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Projecting the Global Cardiac Ablation Devices Market Size to Expand at a 13.25% CAGR Through 2032, DelveInsight Analysis
The global cardiac ablation devices market is predicted to grow from USD 3,832.19 million in 2024 to USD 10,317.88 million by 2032, expanding at a CAGR of 13.25% during the forecast period. This growth is driven by the increasing incidence of cardiovascular diseases, particularly atrial fibrillation, and a rising preference for minimally invasive treatment options, supported by ongoing technological advancements in ablation systems. North America currently leads the market, benefiting from a high prevalence of cardiovascular diseases, established healthcare infrastructure, and quick adoption of advanced medical technologies.
AtriCure (NASDAQ:ATRC) Rating Lowered to "Buy" at Wall Street Zen
Wall Street Zen downgraded AtriCure (NASDAQ:ATRC) from a "strong-buy" to a "buy" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $48.43. Despite beating Q4 EPS estimates with $0.06 against a -$0.04 consensus and revenue of $140.5M, the company remains unprofitable with analysts forecasting -$0.6 EPS for the current year. Shares are trading near their 52-week low at $28.88.
Projecting the Global Cardiac Ablation Devices Market Size to Expand at a 13.25% CAGR Through 2032, DelveInsight Analysis
The global cardiac ablation devices market is projected to reach USD 10,317.88 million by 2032, growing at a CAGR of 13.25% from 2025 to 2032. This growth is driven by the increasing prevalence of cardiovascular diseases and atrial fibrillation, along with advancements in technologies like pulsed-field ablation and sophisticated mapping systems. North America is currently the leading market, accounting for approximately 41% of the total market share in 2024.
Projecting the Global Cardiac Ablation Devices Market Size to Expand at a 13.25% CAGR Through 2032, DelveInsight Analysis
The global cardiac ablation devices market is projected to reach USD 10,317.88 million by 2032, growing at a CAGR of 13.25% from 2025 to 2032. This expansion is driven by the increasing incidence of cardiovascular diseases, particularly atrial fibrillation, and advancements in minimally invasive treatment technologies like radiofrequency, cryoablation, and pulsed field ablation. North America, led by the United States, currently dominates the market due to the high prevalence of cardiovascular diseases and robust healthcare infrastructure.
Vanguard disaggregates holdings; AtriCure (NASDAQ: ATRC) shows 0 shares
The Vanguard Group has filed an amended Schedule 13G/A for AtriCure Inc. (NASDAQ: ATRC), reporting 0 shares beneficially owned. This change reflects an internal realignment on January 12, 2026, where Vanguard disaggregated reporting by its subsidiaries. As a result, Vanguard itself no longer reports beneficial ownership of shares held by these subsidiaries, which will now file their holdings separately.
AtriCure, Inc. Experiences Revision in Stock Evaluation Amidst Market Challenges
AtriCure, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a stock evaluation revision amidst significant market challenges. Its stock price has declined, showing a negative return of -14.01% over the past year, in sharp contrast to the S&P 500's gains. Technical indicators predominantly suggest a bearish sentiment for the stock, especially over longer time frames where returns have been substantially negative.
ATRC Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial analysis of AtriCure Inc (ATRC), detailing its revenue breakdown, profitability margins, and a comparison with competitors. AtriCure generates the majority of its revenue from Appendage Management-United States and maintains strong gross margins, although its net margin and ROE are lower. The analysis highlights ATRC's position within the Medical Equipment industry alongside competitors like TNDM and PLSE.
A Look At AtriCure (ATRC) Valuation After Recent Share Price Weakness And Conflicting Fair Value Signals
AtriCure (ATRC) has experienced recent share price weakness, with its stock declining over the past year. While one valuation narrative suggests the company is 45% undervalued with a fair value of $52.78 due to future growth prospects, a separate discounted cash flow model indicates a starkly different value of just $0.86 per share, highlighting conflicting signals for investors. The article advises investors to review the underlying data to make an informed decision on whether the current weakness represents an undervalued entry point or if the market is appropriately pricing future growth and risks.
AtriCure Chief Scientific Officer Stock Sale - March 2026 Transaction Details - News and Statistics
AtriCure's Chief Scientific Officer, Doraiswamy Vinayak, sold 5,000 shares of company stock on March 12, 2026, marking his largest single sale in the past year. This transaction reduced his direct holdings by 4.9% to 96,875 shares, with the stock priced at $29.83 per share amid negative returns for the company over the last year. AtriCure, specializing in cardiac medical devices, had a market valuation of $1.47 billion at the time of the sale.
AtriCure unveils case-based training to build Afib program skills
AtriCure has introduced a specialized training course designed to improve surgical expertise in managing atrial fibrillation (Afib). The program utilizes case-based learning, expert-led discussions, and practical strategies, covering areas like sinus rhythm restoration and left atrial appendage management. This initiative aims to equip clinicians with the necessary skills to develop and enhance Afib treatment programs, addressing a growing need in the medical field.
AtriCure Stock Forms Death Cross, Signaling Bearish Trend Ahead
AtriCure, Inc. has experienced a Death Cross, a technical event signaling a bearish trend, with its short-term moving average crossing below its long-term moving average. This is supported by other bearish indicators like MACD and a mildly bearish On-Balance Volume. The company's stock has also underperformed the S&P 500 significantly over the past year, declining 12.43% compared to the S&P 500's 18.34% gain, and is down 25.23% year-to-date.
Trading the Move, Not the Narrative: (ATRC) Edition
This article analyzes Atricure Inc. (NASDAQ: ATRC), highlighting a positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. It provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The analysis indicates elevated downside risk due to the absence of additional long-term support signals.
AtriCure CSO Doraiswamy sells $149k in stock By Investing.com
AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, sold 5,000 shares of company stock for $149,150, trading at a weighted average price of $29.83. This transaction occurred while the stock is near its 52-week low and down significantly year-to-date. Despite the sale, Doraiswamy still directly owns 96,875 shares, and analysts view the stock as undervalued with high price targets.
AtriCure CSO Doraiswamy sells $149k in stock
AtriCure Chief Scientific Officer Vinayak Doraiswamy sold 5,000 shares of company stock for a total of $149,150. This transaction occurred on March 12, 2026, with the stock trading near its 52-week low. The sale follows recent robust Q4 2025 financial results that exceeded analyst expectations, though several analysts have adjusted price targets due to competitive concerns and valuation compression.
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $29.83
AtriCure, Inc.'s Chief Scientific Officer, Doraiswamy Vinayak, reported an open-market sale of 5,000 shares of common stock. The shares were sold at a weighted average price of $29.83, with individual trades ranging from $29.79 to $29.92. Following this transaction, Mr. Vinayak directly owns 96,875 shares of AtriCure common stock.
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC)
Vinayak Doraiswamy, Chief Scientific Officer at AtriCure Inc, sold 5,000 shares of ATRC on March 12, 2026, reducing his holdings to 96,875 shares. This sale contributes to a trend of 10 insider sells and no buys at the company over the past year. At the time of the sale, AtriCure Inc shares were trading at $29.83, indicating it was modestly undervalued with a price-to-GF-Value ratio of 0.73 against an estimated GF Value of $40.94.
AtriCure (NASDAQ:ATRC) Insider Vinayak Doraiswamy Sells 5,000 Shares
AtriCure (NASDAQ:ATRC) insider Vinayak Doraiswamy sold 5,000 shares of the company's stock on March 12th for $149,150, reducing his stake by 4.91% to 96,875 shares. The company recently reported strong Q4 2025 earnings, exceeding analyst expectations for EPS and revenue, though it still has negative net margins and ROE. Analyst sentiment is mixed, with a "Moderate Buy" consensus and an average price target of $48.43, but several firms have recently lowered ratings or price targets.
First Light Asset Management LLC Sells 124,808 Shares of AtriCure, Inc. $ATRC
First Light Asset Management LLC reduced its stake in AtriCure, Inc. (NASDAQ:ATRC) by 12.3%, selling 124,808 shares but retaining 890,362 shares valued at approximately $31.39 million, making it their 12th largest holding. Despite this reduction, other institutional investors like Geode Capital, Riverwater Partners, Squarepoint Ops, and Citigroup Inc. increased their positions, with institutional ownership of AtriCure now standing at 99.11%. AtriCure recently reported better-than-expected EPS and increased revenue, maintaining a "Moderate Buy" consensus rating from analysts with an average price target of $48.43.
Kennedy Capital Management LLC Boosts Stock Holdings in AtriCure, Inc. $ATRC
Kennedy Capital Management LLC increased its stake in AtriCure, Inc. (NASDAQ:ATRC) by 36.2% in Q3, owning 836,916 shares worth about $29.5 million. Despite beating EPS estimates in its last quarterly report ($0.06 vs. -$0.04), AtriCure remains unprofitable, with analysts expecting a negative EPS for the current fiscal year. The stock currently trades near its one-year low, below its 50- and 200-day moving averages, and holds a "Moderate Buy" consensus rating from analysts with an average target price of $48.43.
ATRC (NASDAQ: ATRC) files Form 144 reporting proposed sale of award shares
AtriCure, Inc. (ATRC) has filed a Form 144 notice, indicating proposed sales of common stock awards by the Issuer. The filing details various lots of performance shares and restricted stock with specified award dates. While it outlines the quantities of shares intended for sale, it does not confirm actual sale dates or proceeds, which would be visible in subsequent reports.
Director at AtriCure (NASDAQ: ATRC) exercises 10,000 stock options
Robert S. White, a director at AtriCure (NASDAQ: ATRC), exercised 10,000 non-qualified stock options at $14.99 per share. These options were granted on May 25, 2016, and vested over four years. Following this transaction, Mr. White directly holds 122,174 shares of AtriCure common stock.
AtriCure (ATRC) CEO reports family stock gifts in Form 4
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported bona fide gifts of 6,000 shares of AtriCure common stock. These gifts, made to his children and a sibling on March 6, 2026, involved no monetary consideration. Following these transactions, Carrel's direct ownership stands at 778,498 shares, with indirect holdings by family members for which he disclaims beneficial ownership except for his pecuniary interest.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI)
This article summarizes recent analyst sentiments on three healthcare companies: Atricure (ATRC), Q32 Bio (QTTB), and Shoulder Innovations, Inc. (SI). Atricure and Shoulder Innovations received "Strong Buy" ratings with notable price targets, while Q32 Bio received a "Moderate Buy" consensus despite a "Hold" rating from Wells Fargo. The report highlights individual analyst ratings, price targets, and success rates for each company.
ATRC Technical Analysis & ETF Price Forecast
This article provides a technical analysis of AtriCure Inc (ATRC), indicating a "Neutral" overall technical sentiment based on various indicators. While the MACD suggests neutrality, several simple moving averages (5, 10, 20, 60, 200, 250-day) point to a "Buy" signal given the current share price of $29.845. The Relative Strength Index (RSI) and other oscillators also maintain a neutral stance.
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts
AtriCure, Inc. (NASDAQ:ATRC) has received an average "Moderate Buy" rating from analysts, with ten firms covering the stock and setting a mean 12-month price target of $48.43. The company recently reported Q4 EPS of $0.06, surpassing estimates, and revenue of $140.5 million, marking a 13.1% year-over-year increase. Despite trading around $29.39 with a $1.46 billion market cap and a negative P/E, institutional investors have been adjusting their positions.
AtriCure at The Citizens Life Sciences Conference: Strategic Growth Outlook By Investing.com
AtriCure (NASDAQ:ATRC) presented its strategic growth outlook at The Citizens Life Sciences Conference 2026, projecting 12-14% organic growth in 2026, driven by new product launches and existing product adoption, particularly in pain management and appendage management. While acknowledging challenges in the hybrid AFib segment due to PFA headwinds, the company expressed optimism for long-term potential in its CONVERGE procedure and expects crucial data from clinical trials like LEAPS and BoxX-NoAF to validate appendage management benefits. AtriCure's CFO Angela Wirick highlighted innovation, product size reduction, and continued investment in clinical science as key drivers for market leadership.
AtriCure, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
AtriCure, Inc. (Pharmaceuticals & Biotechnology sector) has faced a significant decline in stock evaluation, with a 19.92% return over the past year and a 23.38% year-to-date return, significantly underperforming the S&P 500. Technical indicators show mixed signals, with bearish trends noted in MACD, Bollinger Bands, and Dow Theory, while moving averages suggest a mildly bullish stance. The stock is currently priced at $30.31, down from $30.99, indicating ongoing challenges in a competitive market.
AtriCure (ATRC) CSO granted stock, transfers shares to cover taxes
AtriCure, Inc.'s Chief Scientific Officer, Doraiswamy Vinayak, received significant equity awards, including restricted stock and performance-based shares. To cover tax obligations related to previous vestings, he transferred 15,585 shares back to the company at $31.26 per share. This transaction highlights typical equity compensation and tax management practices for executives.
AtriCure, Inc. $ATRC Position Reduced by GW&K Investment Management LLC
GW&K Investment Management LLC has reduced its stake in AtriCure, Inc. (NASDAQ:ATRC) by 14.6% in the third quarter, selling 147,305 shares and bringing their total ownership to 861,035 shares valued at $30.35 million. Despite this reduction, AtriCure reported positive Q3 EPS of $0.06 against an expected -$0.04, with revenues up 13.1% year-over-year to $140.5 million. The company holds a "Moderate Buy" consensus rating from analysts with an average target price of $48.43.
AtriCure (ATRC) CMO granted stock awards, uses shares to cover taxes
AtriCure, Inc.'s Chief Marketing & Strategy Officer, Justin J. Noznesky, received significant stock awards, including 27,991 restricted shares and 15,198 performance-based shares. To cover tax obligations on these vested awards, he transferred 15,586 shares back to the company at $31.26 per share, resulting in him directly holding 106,401 shares of common stock. This transaction is categorized as an equity compensation and tax withholding event rather than an open-market trade.
AtriCure (ATRC) CTO awarded 45,588 shares, withholds 13,127 for tax
AtriCure, Inc.'s Chief Technical Officer, Salvatore Privitera, received two equity awards totaling 45,588 shares on March 1, 2026: a Restricted Stock Award of 30,390 shares and a Performance Share Award of 15,198 shares, both under the company's 2023 Stock Incentive Plan. To cover tax withholding obligations from previous awards, Privitera transferred 13,127 shares back to AtriCure at $31.26 per share, resulting in a direct ownership of 158,048 shares after these transactions.
AtriCure (ATRC) CEO receives stock awards, uses shares to cover taxes
AtriCure, Inc. President and CEO Michael H. Carrel reported significant equity compensation through restricted stock and performance share awards under the company's 2023 Stock Incentive Plan. To fulfill tax obligations from these vesting awards, Carrel transferred 72,777 shares back to AtriCure at $31.26 per share. Following these transactions, Carrel directly holds 784,498 shares of AtriCure common stock.
AtriCure (ATRC) CLO receives stock awards and surrenders shares for taxes
AtriCure, Inc.'s Chief Legal Officer, Karl S. Dahlquist, reported receiving equity compensation, including 27,991 restricted shares and 15,198 performance-based shares, under the company's 2023 Stock Incentive Plan. He also disposed of 15,687 shares at $31.26 each to cover tax withholding obligations stemming from earlier equity award vestings. The restricted shares will vest in three annual installments, while the performance shares vested upon meeting company goals and service requirements.
A Look At AtriCure (ATRC) Valuation After Strong 2025 Earnings And Upbeat 2026 Outlook
AtriCure (ATRC) reported strong Q4 and full-year 2025 earnings with increased sales and a shift to quarterly profitability, along with positive 2026 guidance. Despite this, the stock has seen recent declines, prompting an evaluation of its current valuation. While a popular narrative suggests the company is 41.4% undervalued based on growth projections, a discounted cash flow (DCF) model indicates it may be overvalued.
AtriCure, Inc. (NASDAQ:ATRC) Short Interest Up 37.3% in February
AtriCure, Inc. (NASDAQ:ATRC) experienced a significant 37.3% increase in short interest during February, reaching 3,447,589 shares, which accounts for 7.2% of its stock. Despite this, institutional investors hold 99.11% of the company's stock, with several major funds increasing their positions in Q4. The company reported a positive EPS of $0.06 against an estimated -$0.04 and a 13.1% revenue growth, although it remains unprofitable.
